Metal ions and oxidative protein modification in neurological disease

Annali dell'Istituto Superiore di Sanita

Volumn 41, Issue 2, 2005, Pages 143-164

  Sayre, Lawrence M ^a   Moreira, Paula I ^a   Smith, Mark A ^a   Perry, George ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Metals; Multiple sclerosis; Neurodegeneration; Oxidative stress; Parkinson's disease

Indexed keywords

2,4 DINITROPHENYLHYDRAZINE; 4 HYDROXYNONENAL; ADVANCED GLYCATION END PRODUCT; AMYLOID BETA PROTEIN; BETA SECRETASE; CERULOPLASMIN; COPPER ION; COPPER ZINC SUPEROXIDE DISMUTASE; FERRITIN; HYDROGEN PEROXIDE; HYDROXYL RADICAL; IRON; LACTOFERRIN; MALONALDEHYDE; MANGANESE; MANGANESE SUPEROXIDE DISMUTASE; METAL ION; METALLOPROTEIN; METHYLGLYOXAL; MITOCHONDRIAL DNA; NITRIC OXIDE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; RNA; SUPEROXIDE; TAU PROTEIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRACE METAL; TRANSFERRIN RECEPTOR; UNINDEXED DRUG;

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; DEMYELINATION; GLUCOSE OXIDATION; HOMEOSTASIS; HUMAN; INFLAMMATION; LIPID OXIDATION; MULTIPLE SCLEROSIS; NERVE CELL DEGENERATION; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PROTEIN MODIFICATION; REVIEW;

ALDEHYDES; ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; ANIMALS; CROSS-LINKING REAGENTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FREE RADICALS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LIPID PEROXIDATION; MALONDIALDEHYDE; METALS; MICE; MULTIPLE SCLEROSIS; NEURODEGENERATIVE DISEASES; OXIDATION-REDUCTION; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEINS; RATS; REACTIVE OXYGEN SPECIES;

EID: 31644435822     PISSN: 00212571     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (276)

1. Andersen JK. Oxidative stress in neurodegeneration: cause or consequence? Nat Med 2004;10 Suppl:S18-25.
2. Sayre LM, Smith MA, Perry G. Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr Med Chem 2001;8(7):721-38.
3. Facheris M, Beretta S, Ferrarese C. Peripheral markers of oxidative stress and excitotoxicity in neurodegenerative disorders: tools for diagnosis and therapy? J Alzheimers Dis 2004;6:177-84.
4. Alvarez B, Radi R. Peroxynitrite reactivity with amino acids and proteins. Amino Acids 2003;25:295-311.
5. Floyd RA. Neuroinflammatory processes are important in neurodegenerative diseases: an hypothesis to explain the increased formation of reactive oxygen and nitrogen species as major factors involved in neurodegenerative disease development. Free Radic Biol Med 1999;26:1346-55.
6. Sayre LM, Perry G, Smith MA. Redox metals and neurodegenerative disease. Curr Opin Chem Biol 1999;3(2):220-5.
7. Sayre LM, Perry G, Atwood CS, Smith MA. The role of metals in neurodegenerative diseases. Cell Mol Biol 2000;46(4):731-41.
8. Corson LB, Folmer J, Strain JJ, Culotta VC, Cleveland DW. Oxidative stress and iron are implicated in fragmenting vacuoles of Saccharomyces cerevisiae lacking Cu,Zn-superoxide dismutase. J Biol Chem 1999;274:27590-6.
9. Papavassiliou AG. Chemical nucleases as probes for studying DNA-protein interactions. Biochem J 1995;305:345-57.
10. Yoshida T, Tanaka M, Sotomatsu A, Hirai S, Okamoto K. Activated microglia cause iron-dependent lipid peroxidation in the presence of ferritin. NeuroReport 1998;9:1929-33.
11. Double KL, Maywald M, Schmittel M, Riederer P, Gerlach M. In vitro studies of ferritin iron release and neurotoxicity. J Neurochem 1998;70:2492-9.
12. Qian ZM, Wang Q. Expression of iron transport proteins and excessive iron accumulation in the brain in neurodegenerative disorders. Brain Res Rev 1998;27:257-67.
13. Pantopoulos K. Iron metabolism and the IRE/IRP regulatory system: an update. Ann N Y Acad Sci 2004;1012:1-13.
14. Nunomura A, Perry G, Pappolla MA, Wade R, Hirai K, Chiba S, Smith MA. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer disease. J Neuroscience 1999;19:1959-64.
15. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001;60:759-67.
16. Nunomura A, Chiba S, Kosaka K, Takeda A, Castellani RJ, Smith MA, Perry G. Neuronal RNA oxidation is a prominent feature of dementia with Lewy bodies. Neuroreport 2002;13(16):2035-9.
17. Stadtman ER. Protein oxidation and aging. Science 1992;257:1220-4.
18. Dalle-Donne I, Scaloni A, Giustarini D, Cavarra E, Tell G, Lungarella G, Colombo R, Rossi R, Milzani A. Proteins as biomarkers of oxidative/nitrosative stress in diseases: the contribution of redox proteomics. Mass Spectrom Rev 2005;24(1):55-99.
19. Hazen SL, Hsu FF, Gaut JP, Crowley JR, Heinecke JW. Modification of proteins and lipids by myeloperoxidase. Methods Enzymol 1999;300:88-105.
20. Butterfield DA. Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain. Brain Res 2004;1000:1-7.
21. Davies MJ. The oxidative environment and protein damage. Biochim Biophys Acta 2005;1703(2):93-109.
22. Fu S-L, Dean RT. Structural characterization of the products of hydroxyl-radical damage to leucine and their detection on proteins. Biochem J 1997;324:41-8.
23. Beckman JS. Oxidative damage and tyrosine nitration from peroxynitrite. Chem Res Toxicol 1996;9:836-44.
24. Ma Y-S, Chao C-C, Stadtman ER. Oxidative modification of glutamine synthetase by 2,2́-azobis(2-amidinopropane) dihydrochloride. Arch Biochem Biophys 1999;363:129-34.
25. Schoneich C. Methionine oxidation by reactive oxygen species: reaction mechanisms and relevance to Alzheimer's disease. Biochim Biophys Acta 2005;1703(2):111-9.
26. Boschi-Muller S, Olry A, Antoine M, Branlant G. The enzymology and biochemistry of methionine sulfoxide reductases. Biochim Biophys Acta 2005;1703(2):231-8.
27. Moskovitz J. Methionine sulfoxide reductases: ubiquitous enzymes involved in antioxidant defense, protein regulation, and prevention of aging-associated diseases. Biochim Biophys Acta 2005;1703(2):213-9.
28. Stadtman ER, Moskovitz J, Levine RL. Oxidation of methionine residues of proteins: biological consequences. Antioxid Redox Signal 2003;5(5):577-82.
29. Malencik DA, Anderson SR. Dityrosine as a product of oxidative stress and fluorescent probe. Amino Acids 2003;25(3-4):233-47.
30. Uchida K, Kawakishi S. Reactions of a histidyl residue analogue with hydrogen peroxide in the presence of copper(II) ion. J Agric Food Chem 1990;38:660-4.
31. Zhao F, Ghezzo-Schoneich E, Aced GL, Hong J, Milby T, Schoneich C. Metal-catalyzed oxidation of histidine in human growth hormone. J Biol Chem 1997;272:9019-29.
32. Huggins TG, Wells-Knecht MC, Detorie NA, Baynes JW, Thorpe SR. Formation of o-tyrosine and dityrosine in proteins during radiolytic and metal-catalyzed oxidation. J Biol Chem 1003;268:12341-7.
33. Buranaprapuk A, Leach SP, Kumar CV, Bocarsly JR. Protein cleavage by transition metal complexes bearing amino acid substituents. Biochim Biophys Acta 1998;1387:309-16.
34. Saxena AK, Saxena P, Wu X, Obrenovich M, Weiss MF, Monnier VM. Protein aging by carboxymethylation of lysines generates sites for divalent metal and redox active copper binding: relevance to diseases of glycoxidative stress. Biochem Biophys Res Commun 1999;260:332-8.
35. ε- (carboxymethyl)lysine increases susceptibility of proteins to metal-catalyzed oxidation. Biochem Biophys Res Commun 1999;264:207-11.
36. Sayre LM, Perry G, Harris PLR, Liu Y, Schubert KA, Smith MA. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer disease: a central role for bound transition metals. J Neurochem 2000;74:270-9.
37. Nagai R, Horiuchi S, Unno Y. Application of monoclonal antibody libraries for the measurement of glycation adducts. Biochem Soc Trans 2003;31(Pt 6):1438-40.
38. ε-(Carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 1996;35:8075-83.
39. ε-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996;271:9982-6.
40. Wells-Knecht KJ, Brinkmann E, Baynes JW. Characterization of an imidazolium salt formed from glyoxal and Nε-hippuryllysine: a model for Maillard reaction crosslinks in proteins. J Org Chem 1995;60:6246-7.
41. Glomb MA, Pfahler C. Amides are novel protein modifications formed by physiological sugars. J Biol Chem 2001;276(45): 41638-47.
42. Liu Y. Modification of proteins by lysine-directed bifunctional aldehydes derived from lipid peroxidation. Ph.D. Thesis, Case Western Reserve University, Cleveland OH, USA, 2003.
43. Ahmed MU, Brinkmann Frye E, Degenhardt TP, Thorpe SR, Baynes JW. N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem J 1997;324:565-70.
44. Brinkmann E, Wells-Knecht KJ, Thorpe SR, Baynes JW. Characterization of an imidazolium compound formed by reaction of methylglyoxal and N*-hippuryllysine. J Chem Soc Perkin Trans 1 1995;2817-8.
45. Pratico D, Lee VMY, Trojanowski JQ, Rokach J, Fitzgerald GA. Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J 1998;12:1777-83.
46. 4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer's disease. J Neurochem 1999;72:734-40.
47. Greco A, Minghetti L, Levi G. Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases. Neurochem Res 2000;25(9-10):1357-64.
48. Montine KS, Quinn JF, Zhang J, Fessel JP, Roberts LJ 2nd, Morrow JD, Montine TJ. Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids 2004;128:117-24.
49. Lee SH, Oe T, Blair IA. Vitamin C-induced decomposition of lipid hydroperoxides to endogenous genotoxins. Science 2001;292(5524):2083-6.
50. Petersen DR, Doorn JA. Reactions of 4-hydroxynonenal with proteins and cellular targets. Free Radic Biol Med 2004;37(7): 937-45.
51. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free Radic Biol Med 1991;11:81-128.
52. Requena JR, Fu MX, Ahmed MU, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR. Quantification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoprotein. Biochem J 1997;322:317-25.
53. Slatter DA, Murray M, Bailey AJ. Formation of a dihydropyridine derivative as a potential cross-link derived from malondialdehyde in physiological systems. FEBS Lett 1998;421:180-4.
54. Itakura K, Uchida K. Evidence that malondialdehyde-derived aminoenimine is not a fluorescent age pigment. Chem Res Toxicol 2001;14(5):473-5.
55. ε-(2-propenal)lysine in proteins. Arch Biochem Biophys 1997;346:45-52.
56. Kikugawa K, Beppu M. Involvement of lipid oxidation products in the formation of fluorescent and cross-linked proteins. Chem Phys Lipids 1987;44:277-6.
57. Nair V, Offerman RJ, Turner GA, Pryor AN, Baenziger NC. Fluorescent 1,4-dihydropyridines: the malondialdehyde connection. Tetrahedron 1988;44:2793-803.
58. Xu D, Thiele GM, Kearley ML, Haugen MD, Klassen LW, Sorrell MF, Tuma DJ. Epitope characterization of malondialdehyde-acetaldehyde adducts using an enzyme-linked immunosorbent assay. Chem Res Toxicol 1997;10:978-86.
59. Itakura K, Uchida K, Osawa T. A novel fluorescent malondialdehyde-lysine adduct. Chem Phys Lipids 1996;84:75-9.
60. Slatter DA, Avery NC, Bailey AJ. Identification of a new cross-link and unique histidine adduct from bovine serum albumin incubated with malondialdehyde. J Biol Chem 2004;279(1): 61-9.
61. Uchida K, Kanematsu M, Sakai K, Matsuda T, Hattori N, Mizuno Y, Suzuki D, Miyata T, Noguchi N, Niki E, Osawa T. Protein-bound acrolein: potential markers for oxidative stress. Proc Natl Acad Sci U S A 1998;95:4882-7.
62. Calingasan NY, Uchida K, Gibson GE. Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease. J Neurochem 1999;72:751-6.
63. ε-(3-methylpyridinium)lysine, a major antigenic adduct generated in acrolein-modified protein. J Biol Chem 2003;278:48658-65.
64. Liu Z, Sayre LM. Model studies on the modification of proteins by lipoxidation-derived 2-hydroxyaldehydes. Chem Res Toxicol 2003;16:232-41.
65. Itakura K, Furuhata A, Shibata N, Kobayashi M, Uchida K. Maillard reaction-like lysine modification by a lipid peroxidation product: immunochemical detection of protein-bound 2-hydroxyheptanal in vivo. Biochem Biophys Res Commun 2003;308:452-7.
66. Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog Lipid Res 2003;42:318-43.
67. Uchida K, Stadtman ER. Modification of histidine residues in proteins by reaction with 4-hydroxynonenal. Proc Natl Acad Sci U S A 1992;89:4544-8.
68. Uchida K, Szweda LI, Chae H-Z, Stadtman ER. Immunochemical detection of 4-hydroxynonenal protein adducts in oxidized hepatocytes. Proc Natl Acad Sci U S A 1993;90:8742-6.
69. Uchida K, Itakura K, Kawakishi S, Hiai H, Toyokuni S. Stadtman ER. Characterization of epitopes recognized by 4-hydroxy-2-nonenal specific antibodies. Arch Biochem Biophys 1995;324:241-8.
70. Nadkarni DV, Sayre LM, Structural definition of early lysine and histidine adduction chemistry of 4-hydroxynonenal. Chem Res Toxicol 1995;8:284-91.
71. Sayre LM, Arora PK, Iyer RS, Salomon RG. Pyrrole formation from 4-hydroxynonenal and primary amines. Chem Res Toxicol 1993;6:19-22.
72. Sayre LM, Sha W, Xu G, Kaur K, Nadkarni D, Subbanagounder G, Salomon RG. Immunochemical evidence supporting 2-pentylpyrrole formation on proteins exposed to 4-hydroxy-2-nonenal. Chem Res Toxicol 1996;9:1194-201.
73. Uchida K, Stadtman ER. Covalent attachment of 4-hydroxynonenal to glyceraldehyde-3-phosphate dehydrogenase. J Biol Chem 1993;268:6388-93.
74. Friguet B, Stadtman ER, Szweda LI. Modification of glucose-6-phosphate dehydrogenase by 4-hydroxynonenal. J Biol Chem 1994;269:21639-43.
75. Cohn JA, Tsai L, Friguet B, Szweda LI. Chemical characterization of a protein-4-hydroxy-2-nonenal cross-link: immunochemical detection in mitochondria exposed to oxidative stress. Arch Biochem Biophys 1996;328:158-64.
76. Montine TJ, Amarnath V, Martin ME, Strittmatter WJ, Graham DG. E-4-Hydroxy-2-nonenal is cytotoxic and crosslinks cytoskeletal proteins in P19 neuroglial cultures. Am J Pathol 1996;148:89-93.
77. Montine TJ, Huang DY, Valentine WM, Amarnath V, Saunders A, Weisgraber KH, Graham DG, Strittmatter WJ. Crosslinking of apolipoprotein E by products of lipid peroxidation. J Neuropathol Exp Neurol 1996;55:202-10.
78. Xu G, Sayre LM. Structural characterization of a 4-hydroxy-2-alkenal- derived fluorophore that contributes to lipoperoxidation-dependent protein crosslinking in aging and degenerative disease. Chem Res Toxicol 1998;11:247-51.
79. ε-hippuryllysine: A model for fluorophores derived from protein modification by lipid peroxidation. J. Org. Chem 1998;63:185-7.
80. Tsai L, Szweda PA, Vinogradova O, Szweda LI. Structural characterization and immunochemical detection of a fluorophore derived from 4-hydroxy-2-nonenal and lysine. Proc Natl Acad Sci U S A 1998;95:7975-80.
81. Xu G, Liu Y, Sayre LM. Independent synthesis, solution behavior, and studies on the mechanism of formation of a primary amine-derived fluorophore representing crosslinking of proteins by (E)-4-hydroxy-2-nonenal (HNE). J Org Chem 1999;64:5732-45.
82. Xu G, Liu Y, Kansal MM, Sayre LM. Rapid crosslinking of proteins by 4-ketoaldehydes and 4-hydroxy-2-alkenals does not arise from the lysine-derived monoalkylpyrroles. Chem Res Toxicol 1999;12:855-61.
83. Montine KS, Kim PJ, Olson SJ, Markesbery WR, Montine TJ. 4-Hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease. J Neuropathol Exp Neurol 1997;56:866-71.
84. Montine KS, Olson SJ, Amarnath V, Whetsell WO Jr, Graham DG, Montine TJ. Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disese is associated with inheritance of APOE4. Am J Pathol 1997;150:437-43.
85. Montine KS, Reich E, Neely MD, Sidell KR, Olson SJ, Markesbery WR, Montine TJ. Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer disease is associated with APOE genotype. J Neuropathol Exp Neurol 1998;57:415-25.
86. Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 1997;68:2092-7.
87. Ando Y, Brannstrom T, Uchida K, Nyhlin N, Nasman B, Suhr O, Yamashita T, Olsson T, El Salhy M, Uchino M, Ando M. Histochemical detection of 4-hydroxynonenal protein in Alzheimer amyloid. J Neurol Sci 1998;156:172-76.
88. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci U S A 1996;93:2696-701.
89. Castellani RJ, Perry G, Siedlak SL, Nunomura A, Shimohama S, Zhang J, Montine T, Sayre LM, Smith MA. Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neurosci Lett 2002;319:25-8.
90. Pedersen WA, Fu W, Keller JN, Markesbery WR, Appel S, Smith RG, Kasarskis E, Mattson MP. Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann Neurol 1998;44:819-24.
91. Ando Y, Nyhlin N, Suhr O, Holmgren G, Uchida K, El Sahly M, Yamashita T, Terasaki H, Nakamura M, Uchino M, Ando M. Oxidative stress is found in amyloid deposits in systemic amyloidosis. Biochem Biophys Res Commun 1997;232:497-502.
92. Castellani RJ, Perry G, Harris PL, Cohen ML, Sayre LM, Salomon RG, Smith MA. Advanced lipid peroxidation end-products in Alexander's disease. Brain Res 1998;787:15-8.
93. Lee SH, Blair IA. Characterization of 4-oxo-2-nonenal as a novel product of lipid peroxidation. Chem Res Toxicol 2000;13:698-702.
94. Spiteller P, Kern W, Reiner J, Spiteller G . Aldehydic lipid peroxidation products derived from linoleic acid. Biochim Biophys Acta 2001;1531:188-208.
95. Zhang WH, Liu J, Xu G, Yuan Q, Sayre LM. Model studies on protein side chain modification by 4-oxo-2-nonenal. Chem Res Toxicol 2003;16:512-23.
96. Liu Z, Minkler PE, Sayre LM. Mass spectroscopic characterization of protein modification by 4-hydroxy-2-(E)-nonenal and 4-oxo-2-(E)-nonenal. Chem Res Toxicol 2003;16(7):901-11.
97. Mattana J, Margiloff L, Singhal PC. Metal-catalyzed oxidation of extracellular matrix proteins disrupts integrin-mediated adhesion of mesangial cells. Biochem Biophys Res Commun 1997;233:50-55.
98. Van L-J, Lodge JK, Traber MG, Packer L. Apolipoprotein B carbonyl formation is enhanced by lipid peroxidation during copper-mediated oxidation of human low-density lipoprotein. Arch Biochem Biophys 1997;339:165-71.
99. Gotz J, Schild A, Hoerndli F, Pennanen L. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models. Int J Dev Neurosci 2004;22(7):453-65.
100. German DC, Eisch AJ. Mouse models of Alzheimer's disease: insight into treatment. Rev Neurosci 2004;15(5):353-69.
101. Selkoe DJ. Defining molecular targets to prevent Alzheimer disease. Arch Neurol 2005;62:(2):192-5.
102. Bishop GM, Robinson SR. Physiological roles of amyloid-beta and implications for its removal in Alzheimer's disease. Drugs Aging 2004;21(10):621-30.
103. Kim HJ, Chae SC, Lee DK, Chromy B, Lee SC, Park YC, Klein WL, Krafft GA, Hong ST. Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. FASEB J 2003;17:118-20.
104. Kirkitadze MD, Bitan G, Teplow DB. Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies. J Neurosci Res 2002;69(5):567-77.
105. Butterfield DA, Boyd-Kimball D. Amyloid beta-peptide(1-42) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain. Brain Pathol 2004;14(4):426-32.
106. King ME. Can tau filaments be both physiologically beneficial and toxic? Biochim Biophys Acta 2005;1739(2-3):260-7.
107. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000;33:95-130.
108. Brandt R, Leger J, Lee G. Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain. J Cell Biol 1995;131:1327-40.
109. Xie H-q, Litersky JM, Hartigan JA, Jope RS, Johnson GVW. The interrelationship between selective tau phosphorylation and microtubule association. Brian Res 1998;798:173-83.
110. Sengupta A, Kabat J, Novak M, Wu Q, Grundke-Iqbal I, Iqbal K. Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch Biochem Biophys 1998;357:299-309.
111. Hanger DP, Betts JC, Loviny TLF, Blackstock WP, Anderton BH. New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J Neurochem 1998;71:2465-76.
112. Stoothoff WH, Johnson GV. Tau phosphorylation: physiological and pathological consequences. Biochim Biophys Acta 2005;1739:280-97.
113. Binder LI, Guillozet-Bongaarts AL, Garcia-Sierra F, Berry RW. Tau, tangles, and Alzheimer's disease. Biochim Biophys Acta 2005;1739:216-23.
114. Nuydens R, De Jong M, Nuyens R, Cornelissen F, Geerts H. Neuronal kinase stimulation leads to aberrant tauphosphorylation and neurotoxicity. Neurobiol Aging 1995;16:465-75.
115. Iqbal K, Zaidi T, Bancher C, Grundke-Iqbal I. Alzheimer paried helical filaments. Restoration of the biological activity by dephosphorylation. FEBS Lett 1994;349:104-8.
116. Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkad E, Gong CX, Khatoon S, Li B, Liu F, Rahman A, Tanimukai H, Grundke-Iqbal I. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 2005;1739:198-210.
117. Kosik KS, Shimura H. Phosphorylated tau and the neurodegenerative foldopathies. Biochim Biophys Acta 2005;1739:298-310.
118. Path T, Eidenmuller J, Brandt RB. Tau-mediated cytotoxicity in a pseudohyperphosphorylation model of Alzheimer's disease. J Neurosci 2002;22:9733-41.
119. Keck S, Nitsch R, Grune T, Ullrich O. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J Neurochem 2003;85:115-22.
120. Miller ML, Johnson GVW. Transglutaminase cross-linking of the t protein. J Neurochem 1995;65:1760-70.
121. Nemes Z, Devreese B, Steinert PM, Van Beeumen J, Fesus L. Cross-linking of ubiquitin, HSP27, parkin, and alpha-synuclein by gamma-glutamyl-epsilon- lysine bonds in Alzheimer's neurofibrillary tangles. FASEB J 2004;18:1135-7.
122. Perry G, Raina AK, Nunomura A, Wataya T, Sayre LM, Smith MA. How important is oxidative damage? Lessons from Alzheimer's disease. Free Radic Biol Med 2000;28:831-4.
123. Ko L-w, Ko EC, Nacharaju P, Liu W-K, Chang E, Kenessy A, Yen S-HC. An immunochemical study on tau glycation in paired helical filaments. Brain Res 1999;830:301-13.
124. Liu Q, Smith MA, Avila J, DeBernardis J, Kansal M, Takeda A, Zhu X, Nunomura A, Honda K, Moreira PI, Oliveira CR, Santos MS, Shimohama S, Aliev G, de la Torre J, Ghanbari HA, Siedlak SL, Harris PL, Sayre LM, Perry G. Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations. Free Radic Biol Med 2005;38(6):746-54.
125. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 1998;158:47-52.
126. Connor JR, Milward EA, Moalem S, Sampietro M, Boyer P, Percy ME, Vergani C, Scott RJ, Chorney M. Is hemochromatosis a risk factor for Alzheimer's disease? J Alzheimers Dis 2001;3:471-7.
127. Perez M, Valpuesta JM, de Garcini EM, Quintana C, Arrasate M, Lopez Carrascosa JL, Rabano A, Garcia de Yebenes J, Avila J. Ferritin is associated with the aberrant tau filaments present in progressive supranuclear palsy. Am J Pathol 1998;152:1531-9.
128. Castellani RJ, Smith MA, Nunomura A, Harris PLR, Perry G. Is increased redox-active iron in Alzheimer disease a failure of the copper-binding protein ceruloplasmin? Free Radic Biol Med 1999;26:1508-12.
129. Smith MA, Wehr K, Harris PLR, Siedlak SL, Connor JR, Perry G. Abnormal localization of iron regulatory protein (IRP) in Alzheimer disease. Brain Res 1998;788:232-6.
130. Smith MA, Kutty RK, Richey PL, Yan S-D, Stern D, Chader GJ, Wiggert B, Petersen RB, Perry G. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer disease. Am J Pathol 1994;145:42-7.
131. Premkumar DRD, Smith MA, Richey PL, Petersen RB, Castellani R, Kutty RK, Wiggert B, Perry G, Kalaria RN. Induction of heme oxygenase-1 mRNA and protein in neocortex and cerebral vessels in Alzheimer's disease. J Neurochem 1995;65:1399-402.
132. Honda K, Casadesus G, Petersen RB, Perry G, Smith MA. Oxidative stress and redox-active iron in Alzheimer's disease. Ann N Y Acad Sci 2004;1012:179-82.
133. Good PF, Perl DP, Bierer LM, Schmeidler J. Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: a laser microprobe (LAMMA) study. Ann Neurol 1992;31:286-92.
134. Oteiza PI. A mechanism for the stimulatory effect of aluminum on iron-induced lipid peroxidation. Arch Biochem Biophys 1994;308:374-9.
135. Smith MA, Harris PLR, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A 1997;94:9866-8.
136. Mantyh PW, Ghilardi JR, Rogers S, DeMaster E, Allen CJ, Stimson ER, Maggio JE. Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide. J Neurochem 1993;61:1171-4.
137. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NME, Romano DM, Hartshorn MA, Tanzi RE, Bush AI. Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 1998;273:12817-26.
138. Cherny RA, Legg JT, McLean CA, Fairlic DP, Huang X, Atwood CS, Beyreuther K, Tanzi RE, Masters CL, Bush AI. Aqueous dissolution of Alzheimer's disease Aβ amyloid deposits by biometal depletion. J Biol Chem 1999;274:23223-8.
139. Dong J, Atwood CS, Anderson VE, Siedlak SL, Smith MA, Perry G, Carey PR. Metal binding and oxidation of amyloid-β within isolated senile plaque cores: Raman microscopic evidence. Biochemistry 2003;42:2768-73.
140. Bishop GM, Robinson SR. The amyloid paradox: amyloid-beta-metal complexes can be neurotoxic and neuroprotective. Brain Pathol 2004;14(4):448-52.
141. Bondy SC, Guo-Ross SX, Truong AT. Promotion of transition metal-induced reactive oxygen species formation by β-amyloid. Brain Res 1998;799:91-6.
142. Yang EY, Guo-Ross SX, Bondy SC. The stabilization of ferrous iron by a toxic β-amyloid fragment and by an aluminum salt. Brain Res 1999;839:221-6.
143. Huang X, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, Cuajungco MP, Gray DN, Lim J, Moir RD, Tanzi RE, Bush AI. The Aβ peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999;38:7609-16.
144. House E, Collingwood J, Khan A, Korchazkina O, Berthon G, Exley C. Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer's disease. J Alzheimer Dis 2004;6(3):291-301.
145. Bayer TA, Schafer S, Simons A, Kemmling A, Kamer T, Tepest R, Eckert A, Schussel K, Eikenberg O, Sturchler-Pierrat C, Abramowski D, Staufenbiel M, Multhaup G. Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice. Proc Natl Acad Sci U S A 2003;100:14187-92.
146. Sparks DL, Schreurs BG. Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc Natl Acad Sci U S A 2003;100:11065-9.
147. Bellingham SA, Lahiri DK, Maloney B, La Fontaine S, Multhaup G, Camakaris J. Copper depletion down-regulates expression of the Alzheimer's disease amyloid-beta precursor protein gene. J Biol Chem 2004;279(19):20378-86.
148. Multhaup G, Ruppert T, Schlicksupp A, Hesse L, Bill E, Pipkorn R, Masters CL, Beyreuther K. Copper-binding amyloid precursor undergoes a site-specific fragmentation in the reduction of hydrogen peroxide. Biochemistry 1998;37:7224-30.
149. Multhaup G, Ruppert T, Schlicksupp A, Hesse L, Beher D, Masters CL, Beyreuther K. Reactive oxygen species and Alzheimer's disease. Biochem Pharmacol 1997;54:533-59.
150. Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, Leiter L, McPhee J, Sarang SS, Utsuki T, Greig NH, Lahiri DK, Tanzi RE, Bush AI, Giordano T, Gullans SR. An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem 2002;277:45518-28.
151. Sayre LM, Perry G, Smith MA. In situ methods for detection and localization of markers of oxidative stress: application in neurodegenerative disorders. Methods Enzymol 1999;309:133-52.
152. Gabbita SP, Lovell MA, Markesbery WR. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J Neurochem 1998;71:2034-40.
153. Lovell MA, Gabbita SP, Markesbery WR. Increased DNA oxidation and decreassed levels of repair products in Alzheimer's disease ventricular CSF. J Neurochem 1999;72:771-6.
154. Smith MA, Perry G, Richey PL, Sayre LM, Anderson VE, Beal MF, Kowall N. Oxidative damage in Alzheimer's. Nature 1996;382:120-1.
155. Smith MA, Harris PLR, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 1997;17:2653-7.
156. Hensley K, Maidt ML, Yu Z, Sang H, Markesbery WR, Floyd RA. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci 1998;18:8126-32.
157. Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, Markesbery WR. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 2005;64(7):1152-6.
158. Smith MA, Taneda S, Richey PL, Miyata S, Van S-D, Stern D, Sayre LM, Monnier VM, Perry G. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci U S A 1994;91:5710-4.
159. Smith MA, Rudnicka-Nawrot M, Richey PL, Praprotnik D, Mulvihill R Miller CA, Sayre LM, Perry G. Carbonyl-related posttranslational modification of neurofilament protein in the neurofibrillary pathology of Alzheimer's disease. J Neurochem 1995;64:2660-6.
160. Smith MA, Sayre LM, Monnier VM, Perry G. Radical AGEing in Alzheimer's disease. Trends Neurosci 1995;18:172-6.
161. Vitek MP, Bhattacharya K, Glendening JM, Stopa E, Vlassara H, Bucala R, Manogue K, Cerami A. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A 1994;91:4766-70.
162. Van S-D, Chen X, Schmidt A-M, Brett J, Godman G, Zou Y-S, Scott C W, Caputo C, Frappier T, Smith M A, Perry G, Yen S-H, Stern D. Glycated τ protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci U S A 1994;91:7787-91.
163. Ledesma MD, Bonay P, Colaco C, Avila J. Analysis of microtubule- associated protein τ glycation in paired helical filaments. J Biol Chem 1994;269:21614-9.
164. Castellani RJ, Harris PL, Sayre LM, Fujii J, Taniguchi N, Vitek MP, Founds H, Atwood CS, Perry G, Smith MA. Active glycation in neurofibrillary pathology of Alzheimer disease: N(epsilon)-(carboxymethyl) lysine and hexitol-lysine. Free Radic Biol Med 2001;31:175-80.
165. Cras P, Smith MA, Richey PL, Siedlak SL, Mulvihill P, Perry G. Extracellular neurofibrillary tangles reflect neuronal loss and provide further evidence of extensive protein cross-linking in Alzheimer disease. Acta Neuropathol (Berl) 1995;89:291-5.
166. Smith MA. Alzheimer disease. Int Rev Neurobiol 1998;42:1-54.
167. Sullivan PG, Brown MR. Mitochondrial aging and dysfunction in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2005;29(3):407-10.
168. Castellani RJ, Honda K, Zhu X, Cash AD, Nunomura A, Perry G, Smith MA. Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease. Ageing Res Rev 2004;3(3):319-26.
169. Schipper HM, Cisse S, Stopa EG. Expression of heme oxygenase-1 in the senescent and Alzheimer-diseased brain. Ann Neurol 1995;37:758-68.
170. Bonilla E, Tanji K, Hirano M, Vu TH, DiMauro S, Schon EA. Mitochondrial involvement in Alzheimer's disease. Biochim Biophys Acta 1999;1410:171-82.
171. Aliev G, Seyidova D, Neal ML, Shi J, Lamb BT, Siedlak SL, Vinters HV, Head E, Perry G, Lamanna JC, Friedland RP, Cotman CW. Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels as a central target for the development of human AD and AD-like pathology in aged transgenic mice. Ann N Y Acad Sci 2002;977:45-64.
172. Pappolla MA, Omar RA, Kim KS, Robakis NK. Immunohistochemical evidence of oxidative stress in Alzheimer's disease. Am J Pathol 1992;140:621-8.
173. De Leo ME, Borrello S, Passantino M, Palazzotti B, Mordente A, Daniele A, Filippini V, Galeotta T, Masullo C. Oxidative stress and overexpression of manganese superoxide dismutase in patients with Alzheimer's disease. Neurosci Lett 1998;250:173-6.
174. Martins RN, Harper CG, Stokes GB, Masters CL. Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer's disease may reflect oxidative stress. J Neurochem 1986;46:1042-5.
175. Russell RL, Siedlak SL, Raina AK, Bautista JM, Smith MA, Perry G. Increased neuronal glucose-6-phosphate dehydrogenase and sulfhydryl levels indicate reductive compensation to oxidative stress in Alzheimer disease. Arch Biochem Biophys 1999;370:236-9.
176. Raina AK, Templeton DJ, Deak JC, Perry G, Smith MA. Quinone reductase (NQO1), a sensitive redox indicator, is increased in Alzheimer's disease. Redox Report 1999;4:23-7.
177. Marcus DL, Thomas C, Rodriguez C, Simberkoff K, Tsai JS, Strafaci JA, Freedman ML. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp Neurol 1989;150:40-4.
178. Perry G, Taddeo MA, Nunomura A, Zhu X, Zenteno-Savin T, Drew KL, Shimohama S, Avila J, Castellani RJ, Smith MA. Comparative biology and pathology of oxidative stress in Alzheimer and other neurodegenerative diseases: beyond damage and response. Comp Biochem Physiol C Toxicol Pharmacol 2002;133:507-13.
179. Zhu X, Raina AK, Lee HG, Casadesus G, Smith MA, Perry G. Oxidative stress signalling in Alzheimer's disease. Brain Res 2004;1000:32-9.
180. Morsch R, Simon W, Coleman PD. Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol 1999;58:188-97.
181. Wataya T, Nunomura A, Smith MA, Siedlak SL, Harris PL, Shimohama S, Szweda LI, Kaminski MA, Avila J, Price DL, Cleveland DW, Sayre LM, Perry G. High molecular weight neurofilament proteins are physiological substrates of adduction by the lipid peroxidation product hydroxynonenal. J Biol Chem 2002;277:4644-8.
182. Nunomura A, Perry G, Hirai K, Aliev G, Takeda A, Chiba S, Smith MA. Neuronal RNA oxidation in Alzheimer's disease and Down's syndrome. Ann N Y Acad Sci 1999;893:362-4.
183. Nunomura A, Perry G, Pappolla MA, Friedland RP, Hirai K, Chiba S, Smith MA. Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J Neuropathol Exp Neurol 2000;59(11):1011-7.
184. Smith MA, Nunomura A, Zhu X, Takeda A, Perry G. Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer disease. Antioxid Redox Signal 2000;2:413-20.
185. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003;53(Suppl 3):S26-36.
186. Galloway PG, Mulvihill P, Perry G. Filaments of Lewy bodies contain insoluble cytoskeletal elements. Am J Pathol 1992;140:809-22.
187. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003;302:819-22.
188. Schapira AH. Causes of neuronal death in Parkinson's disease. Adv Neurol 2001;86:155-62.
189. Beal MF. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J Bioenerg Biomembr 2004;36(4):381-6.
190. Sanchez-Ramos J, Overvik E, Ames B. A marker of oxyradical-mediated DNA damage (8-hydroxy-2′-deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 1994;3:197-204.
191. Zhang J, Perry G, Smith MA, Robertson D, Olson SJ, Graham DG, Montine TJ. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 1999;154:1423-9.
192. Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, Halliwell B. A generalized increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 1997;69:1326-9.
193. Floor E, Wetzel MG. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem 1998;70:268-75.
194. Good PF, Hsu A, Werner P, Perl DP, Olanow CW. Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol 1998;57:338-42.
195. Castellani R, Smith MA, Richey PL, Perry G. Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res 1996;737:195-200.
196. Burke RE. Recent advances in research on Parkinson disease: synuclein and parkin. Neurologist 2004;10:75-81.
197. Zhou W, Hurlbert MS, Schaack J, Prasad KN, Freed CR. Overexpression of human α-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. Brain Res 2000;866:33-43.
198. Lee M, Hyun D, Halliwell B, Jenner P. Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J Neurochem 2001;76:998-1009.
199. Recchia A, Debetto P, Negro A, Guidolin D, Skaper SD, Giusti P. Alpha-synuclein and Parkinson's disease. FASEB J 2004;18:617-26.
200. Zhou W, Freed CR. Tyrosine-to-cysteine modification of human alpha-synuclein enhances protein aggregation and cellular toxicity. J Biol Chem 2004;279:10128-35.
201. Jensen PH, Hager H, Nielsen MS, Hojrup P, Gliemann J, Jakes R. α-Synuclein binds to tau and stimulates the protein kinase A-catalyzed tau phosphorylation of Ser 262 and 356. J Biol Chem 1999;274(36):25481-9.
202. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, Lee VM. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 2003;300:636-40.
203. Iseki E, Marui W, Kosaka K, Uéda K. Frequent coexistence of Lewy bodies and neurofibrillary tangles in the same neurons of patients with diffuse Lewy body disease. Neurosci Lett 1999;265:9-12.
204. Lee VM, Giasson BI, Trojanowski JQ. More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases. Trends Neurosci 2004;27:129-34.
205. Paik SR, Shin H-J, Lee J-H, Chang C-S, Kim J. Copper(II)-induced self-oligomerization of a-synuclein. Biochem J 1999;340:821-8.
206. Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sisk A, Sundsmo M, Masliah E. Oxidative stress induces amyloid-like aggregate formation of NACP/a-synuclein in vitro. NeuroReport 1999;10:717-21.
207. Hashimoto M, Takeda A, Hsu LJ, Takenouchi T, Masliah E. Role of cytochrome c as a stimulator of α-synuclein aggregation in Lewy body disease. J Biol Chem 1996;274:28849-52.
208. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000;290:985-9.
209. Hodara R, Norris EH, Giasson BI, Mishizen-Eberz AJ, Lynch DR, Lee VM, Ischiropoulos H. Functional consequences of α-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J Biol Chem 2004;279:47746-53.
210. Hattori N, Mizuno Y. Pathogenetic mechanisms of parkin in Parkinson's disease. Lancet 2004;364:722-4.
211. McNaught KS, Olanow CW. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. Ann Neurol 2003;53(Suppl 3):S73-84.
212. Hyun DH, Gray DA, Halliwell B, Jenner P. Interference with ubiquitination causes oxidative damage and increased protein nitration: implications for neurodegenerative diseases. J Neurochem 2004;90:422-30.
213. McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 2003;179:38-46.
214. Lindersson E, Beedholm R, Hojrup P, Moos T, Gai W, Hendil KB, Jensen PH. Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem 2004;279:12924-34.
215. Rideout HJ, Dietrich P, Wang Q, Dauer WT, Stefanis L. α-Synuclein is required for the fibrillar nature of ubiquitinated inclusions induced by proteasomal inhibition in primary neurons. J Biol Chem 2004;279:46915-20.
216. Eriksen JL, Wszolek Z, Petrucelli L. Molecular pathogenesis of Parkinson disease. Arch Neurol 2005;62(3):353-7.
217. Schipper HM. Astrocytes, brain aging, and neurodegeneration. Neurobiol Aging 1996;17:467-80.
218. Schipper HM, Vininsky R, Brull R, Small L, Brawer JR. Astroctye mitochondria: a substrate for iron deposition in the aging rat substantia nigra. Exp Neurol 1998;152:188-96.
219. Riederer P, Sofic E, Rausch W-D, Schmidt B, Reynold GP, Jellinger K, Youdim MBH. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 1989;52:515-20.
220. Pezzella A, d'Ischia M, Napolitano A, Misuraca G, Prota G. Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by reaction of fatty acid hydroperoxides with dopamine: a possible contributory mechanism for neuronal degeneration in Parkinson's disease. J Med Chem 1997;40:2211-6.
221. Youdim MB, Stephenson G, Ben Shachar D. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci 2004;1012:306-25.
222. Powers KM, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD, Checkoway H. Parkinson's disease risks associated with dietary iron, manganese, and other nutrient intakes. Neurology 2003;60(11):1761-6.
223. Kaur D, Andersen J. Does cellular iron dysregulation play a causative role in Parkinson's disease? Ageing Res Rev 2004;3(3):327-43.
224. Schipper HM. Brain iron deposition and the free radical-mitochondrial theory of ageing. Ageing Res Rev 2004;3(3):265-301.
225. Hegde ML, Shanmugavelu P, Vengamma B, Rao TS, Menon RB, Rao RV, Rao KS. Serum trace element levels and the complexity of inter-element relations in patients with Parkinson's disease. J Trace Elem Med Biol 2004;18(2):163-71.
226. Forte G, Bocca B, Senofonte O, Petrucci F, Brusa L, Stanzione P, Zannino S, Violante N, Alimonti A, Sancesario G. Trace and major elements in whole blood, serum, cerebrospinal fluid and urine of patients with Parkinson's disease. J Neural Transm 2004;111(8):1031-40.
227. Olanow CW. Manganese-induced parkinsonism and Parkinson's disease. Ann N Y Acad Sci 2004;1012:209-23.
228. Dobson AW, Erikson KM, Aschner M. Manganese neurotoxicity. Ann N Y Acad Sci 2004;1012:115-28.
229. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992;10:153-87.
230. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 1996;85(3):299-302.
231. Noseworthy JH. Progress in determining the causes and treatment of multiple sclerosis. Nature 1999;399:A40-7.
232. Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 2004;251(3):261-8.
233. van der Goes A, Brouwer J, Hoekstra K, Roos D, van den Berg TK, Dijkstra CD. Reactive oxygen species are required for the phagocytosis of myelin by macrophages. J Neuroimmunol 1998;92:67-75.
234. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.
235. Winyard PG, Blake DR. Antioxidants, redox-regulated transcription factors, and inflammation. Adv Pharmacol 1997;38:403-21.
236. Syburra C, Passi S. Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh 1999;71(3):112-5.
237. Skukla UK, Jensen GE, Clausen J. Erythrocyte glutathione peroxidase deficiency in multiple sclerosis. Acta Neurol Scand 1997;56(6):542-50.
238. Jensen GE, Clausen J. Glutathione peroxidase and reductase, glucose-6-phosphate dehydrogenase and catalase activity in multiple sclerosis. J Neurol Sci 1984;63(1):45-53.
239. Karg E, Klivenyi P, Nemeth I, Bencsik K, Pinter S, Vecsei L. Nonenzymatic antioxidants of blood in multiple sclerosis. J Neurol 1999;246:533-9.
240. Greco A, Minghetti L, Sette G, Fieschi C, Levi G. Cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis. Neurology 1999;53:1876-9.
241. Calabrese V, Raffaele R, Cosentino E, Rizza V. Changes in cerebrospinal fluid levels of malondialdehyde and glutathione reductase activity in multiple sclerosis. Int J Clin Pharmacol Res 1994;14:119-23.
242. Langemann H, Kabiersch A, Newcombe J. Measurement of low-molecular-weight antioxidants, uric acid, tyrosine and tryptophan in plaques and white matter from patients with multiple sclerosis. Eur Neurol 1992;32:248-52.
243. Lu F, Selak M, O'Connor J, Croul S, Lorenzana C, Butunoi C, Kalman B. Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis. J Neurol Sci 2000;177:95-103.
244. Vladimirova O, Lu FM, Shawver L, Kalman B. The activation of protein kinase C induces higher production of reactive oxygen species by mononuclear cells in patients with multiple sclerosis than in controls. Inflamm Res 1999;48:412-6.
245. Matute C, Perez-Cerda F. Multiple sclerosis: novel perspectives on newly forming lesions. Trends Neurosci 2005;28(4):173-5.
246. Matute C, Alberdi E, Domercq M, Perez-Cerda F, Perez-Samartin A, Sanchez-Gomez MV. The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends Neurosci 2001;24(4):224-30.
247. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343:938-52.
248. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 2000;6:67-70.
249. Smith T, Groom A, Zhu B, Turski L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 2000;6:62-6.
250. Gilgun-Sherki Y, Panet H, Melamed E, Offen D. Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis. Brain Res 2003;989:196-204.
251. Smith KJ, Kapoor R, Felts PA. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 1999;9:69-92.
252. Stover JF, Pleines UE, Morganti-Kossmann MC, Kossmann T, Lowitzsch K, Kempski OS. Neurotransmitters in cerebrospinal fluid reflect pathological activity. Eur J Clin Invest 1997;27:1038-43.
253. Barkhatova VP, Zavalisnin IA, Askarova LSh, Shavratskii VKh, Demina EG. Changes in neurotransmitters in multiple sclerosis. Neurosci Behav Physiol 1998;28:341-4.
254. Werner P, Pitt D, Raine CS. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 2001;50:169-80.
255. Cross AH, Misko TP, Lin RF, Hickey WF, Trotter JL, Tilton RG. Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. J Clin Invest 1994;93:2684-90.
256. Zhao W, Tilton RG, Corbett JA, McDaniel ML, Misko TP, Williamson JR, Cross AH, Hickey WF. Experimental allergic encephalomyelitis in the rat is inhibited by aminoguanidine, an inhibitor of nitric oxide synthase. J Neuroimmunol 1996;64:123-33.
257. Brenner T, Brocke S, Szafer F, Sobel RA, Parkinson JF, Perez DH, Steinman L. Inhibition of nitric oxide synthase for treatment of experimental autoimmune encephalomyelitis. J Immunol 1997;158:2940-6.
258. Ding M, Zhang M, Wong JL, Rogers NE, Ignarro LJ, Voskuhl RR. Antisense knockdown of inducible nitric oxide synthase inhibits induction of experimental autoimmune encephalomyelitis in SJL/J mice. J Immunol 1998;160:2560-4.
259. Hooper DC, Bagasra O, Marini JC, Zborek A, Ohnishi ST, Kean R, Champion JM, Sarker AB, Bobroski L, Farber JL, Akaike T, Maeda H, Koprowski H. Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis. Proc Natl Acad Sci U S A 1997;94:2528-33.
260. Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I, Koprowski H. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A. 1998;95:675-80.
261. Lehmann D, Karussis D, Misrachi-Koll R, Shezen E, Ovadia H, Abramsky O. Oral administration of the oxidant-scavenger N-acetyl-L-cysteine inhibits acute experimental autoimmune encephalomyelitis. J Neuroimmunol 1994;50:35-42.
262. Ruuls SR, Bauer J, Sontrop K, Huitinga I, 't Hart BA, Dijkstra CD. Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats. J Neuroimmunol 1995;56:207-17.
263. Malfroy B, Doctrow SR, Orr PL, Tocco G, Fedoseyeva EV, Benichou G. Prevention and suppression of autoimmune encephalomyelitis by EUK-8, a synthetic catalytic scavenger of oxygen-reactive metabolites. Cell Immunol 1997;177(1):62-8.
264. Marracci GH, Jones RE, McKeon GP, Bourdette DN. Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. J Neuroimmunol 2002;131:104-14.
265. Morini M, Roccatagliata L, Dell'Eva R, Pedemonte E, Furlan R, Minghelli S, Giunti D, Pfeffer U, Marchese M, Noonan D, Mancardi G, Albini A, Uccelli A. Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J Neuroimmunol 2004;148:146-53.
266. Liu Y, Zhu B, Wang X, Luo L, Li P, Paty DW, Cynader MS. Bilirubin as a potent antioxidant suppresses experimental autoimmune encephalomyelitis: implications for the role of oxidative stress in the development of multiple sclerosis. J Neuroimmunol 2003;139:27-35.
267. Jensen GE, Clausen J. Glutathione peroxidase activity, associated enzymes and substrates in blood cells from patients with multiple sclerosis-effects of antioxidant supplementation. Acta Pharmacol Toxicol 1986;59:450-3.
268. Swank RL, Dugan BB. Effect of low saturated fat diet in early and late cases of multiple sclerosis. Lancet 1990;336(8706):37-9.
269. Mai J, Sorensen PS, Hansen JC. High dose antioxidant supplementation to MS patients. Effects on glutathione peroxidase, clinical safety, and absorption of selenium. Biol Trace Elem Res 1990;24:109-17.
270. Spitsin S, Hooper DC, Leist T, Streletz LJ, Mikheeva T, Koprowskil H. Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease. Mult Scler 2001;7(5):313-9.
271. LeVine SM. Iron deposits in multiple sclerosis and Alzheimer's disease brains. Brain Res 1997;760(1-2):298-303.
272. LeVine SM, Lynch SG, Ou CN, Wulser MJ, Tam E, Boo N. Ferritin, transferrin and iron concentrations in the cerebrospinal fluid of multiple sclerosis patients. Brain Res 1999;821(2):511-5.
273. Hulet SW, Powers S, Connor JR. Distribution of transferrin and ferritin binding in normal and multiple sclerotic human brains. J Neurol Sci 1999;165(1):48-55.
274. Melo TM, Larsen C, White LR, Aasly J, Sjobakk TE, Flaten TP, Sonnewald U, Syversen T. Manganese, copper, and zinc in cerebrospinal fluid from patients with multiple sclerosis. Biol Trace Elem Res 2003;93(1-3):1-8.
275. Levine SM, Chakrabarty A. The role of iron in the pathogenesis of experimental allergic encephalomyelitis and multiple sclerosis. Ann N Y Acad Sci 2004;1012:252-66.
276. Behl C. Oxidative stress in Alzheimer's disease: implications for prevention and therapy. Subcell Biochem 2005;38:65-78.